HJ Science Passes HKEX Listing Hearing, Core Products Cover Autoimmune, Metabolic and Oncology Fields

NewTimeSpace News: As disclosed by the Hong Kong Stock Exchange, HJ Science (Chengdu) Technology Co., Ltd. completed the main board listing hearing on May 29, 2026, with CITIC Securities appointed as the sole sponsor.
Established in 2017, HJ Science is a clinical-stage biotechnology company founded by a team of industry experts dedicated to developing therapies for autoimmune, metabolic and oncological diseases.
The company’s three core pipeline products are as follows:
HJ787: A selective TYK2 inhibitor for the treatment of autoimmune diseases including atopic dermatitis, acne, neurodermatitis and psoriasis.
HJ178: An oral dual GLP-1/GIP agonist indicated for type 2 diabetes and overweight/obesity.
HJ891: An oral KRAS G12C inhibitor for non-small cell lung cancer.
In addition, the company has one clinical-stage candidate drug and five pre-clinical candidate drugs in its pipeline.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.